Recently,p.Glu1121Ter in PLXNA1 was identified as po-tential cause for a patient with parkinsonism.However,no further replication has been conducted in a wider range of Parkinson’s disease(PD)cohorts.To evaluate the ...Recently,p.Glu1121Ter in PLXNA1 was identified as po-tential cause for a patient with parkinsonism.However,no further replication has been conducted in a wider range of Parkinson’s disease(PD)cohorts.To evaluate the genetic association of PLXNA1 with PD,we systematically analyzed the rare protein-coding variants in 1,245 Chinese patients with whole exome sequencing.展开更多
Whole-brain irradiation（WBI）,usually delivered in 25–30fractions to accumulate a total dose of 55–60 Gy,is commonly used for the treatment of primary tumors in the central nervous system（CNS）and brain metastases...Whole-brain irradiation（WBI）,usually delivered in 25–30fractions to accumulate a total dose of 55–60 Gy,is commonly used for the treatment of primary tumors in the central nervous system（CNS）and brain metastases.With improved treatment techniques patients have prolonged overall survival,but are more likely to experience late adverse effects.展开更多
基金supported by the funding of the National Key Research and Development Program of China(No.2021YFC2501200)the Sichuan Science and Technology Program(China)(No.2022ZDZX0023,No.2021YJ0415)the National Natural Science Foundation of China(No.81901294,81871000).
文摘Recently,p.Glu1121Ter in PLXNA1 was identified as po-tential cause for a patient with parkinsonism.However,no further replication has been conducted in a wider range of Parkinson’s disease(PD)cohorts.To evaluate the genetic association of PLXNA1 with PD,we systematically analyzed the rare protein-coding variants in 1,245 Chinese patients with whole exome sequencing.
基金supported by National Institutes of Health(NIH),grants:R01CA213441,R01CA133216the Pediatric Brain Tumor Foundation Institute Grant
文摘Whole-brain irradiation（WBI）,usually delivered in 25–30fractions to accumulate a total dose of 55–60 Gy,is commonly used for the treatment of primary tumors in the central nervous system（CNS）and brain metastases.With improved treatment techniques patients have prolonged overall survival,but are more likely to experience late adverse effects.
